DI 23022.830:
Myoclonic Epilepsy with Ragged Red Fibers Syndrome
Effective Dates: 01/06/2017 - Present- Effective Dates: 03/28/2018 - Present
TN 7 (08-12)- TN 16 (03-18)
- DI 23022.830 Myoclonic Epilepsy with Ragged Red Fibers Syndrome
- COMPASSIONATE ALLOWANCE INFORMATION
- MYOCLONIC EPILEPSY WITH RAGGED RED FIBERS SYNDROME
ALTERNATE NAMES- ALTERNATE NAMES
- MERRF; Myoclonus with Epilepsy with Ragged Red Fibers; MERRF Syndrome; Myoencephalopathy Ragged Red Fiber Disease; Fukuhara syndrome
DESCRIPTION- DESCRIPTION
- Myoclonic Epilepsy with Ragged Red Fibers (MERRF) is a rare inherited neurometabolic disorder that affects the central nervous system, skeletal muscles, and other body systems. MERRF is characterized by myoclonic seizures (brief, sudden twitching muscle spasms), weakness (myopathy), cerebellar ataxia, progressive spasticity and dementia. Characteristic abnormal muscle cells appear as ragged red fibers when stained and viewed under a microscope.
DIAGNOSTIC TESTING, PHYSICAL FINDINGS, AND ICD-9-CM CODING- DIAGNOSTIC TESTING, PHYSICAL FINDINGS, AND ICD-9-CM CODING
Diagnostic testing: Muscle biopsy with pathology report documenting structurally abnormal mitochondria; CT/MRI for cerebral atrophy; EEG for seizure activity; blood serum testing for elevated lactate levels; and hearing and vision testing- Diagnostic testing: Muscle biopsy with pathology report documenting structurally abnormal mitochondria; CT/MRI for cerebral atrophy; EEG for seizure activity; blood serum testing for elevated lactate levels; and hearing and vision testing.
- Physical findings: Neurological dysfunction including cerebellar ataxia, dementia, muscle atrophy with muscle weakness, neuropathy, optic atrophy, and short stature.
- ICD-9: 277.87
ONSET AND PROGRESSION- ONSET AND PROGRESSION
- Signs and symptoms of this disorder mostly appear during childhood or adolescence, although sometimes after age 20. Clinical course is variable, from slowly progressive to rapidly downhill.
TREATMENT- TREATMENT
- There is no current cure for MERRF and treatment is supportive. Medications may be prescribed for seizures and to control muscle movement. Physical therapy and occupational therapy can be used to extend the range of muscle movement and improve dexterity. Vitamin therapies such as riboflavin, coenzyme Q, and carnitine may provide subjective improvement in fatigue and energy levels in some individuals.
SUGGESTED PROGRAMMATIC ASSESSMENT*- SUGGESTED PROGRAMMATIC ASSESSMENT*
Suggested MER for evaluation:- Suggested MER for evaluation:
- * Clinical history and examination that describes the diagnostic features of the impairment, and physical and cognitive findings
- * Muscle biopsy showing the presence of ragged red fibers
- * Imaging studies such as CT or MRI
- * EEG results, vision or hearing testing may be helpful
Suggested Listings for Evaluation:- Suggested Listings for Evaluation:
DETERMINATION- DETERMINATION
- LISTING
REMARKSMeets Listing- Meets Listing
- 11.02
- 11.17
- 111.02
- 111.17
Medical Equals- Medical Equals
- 11.17
- 12.02
* Adjudicators may, at their discretion, use the Medical Evidence of Record or Listings suggested to evaluate the claim. However, the decision to allow or deny the claim rests with the adjudicator.- * Adjudicators may, at their discretion, use the Medical Evidence of Record or Listings suggested to evaluate the claim. However, the decision to allow or deny the claim rests with the adjudicator.
x
← This means that the line
was removed and
was added – in other words, the "Effective Dates" line at the top of the document has been updated to reflect that the new version is effective as of the date the change was made.